SOURCE-LINKED STUDY SUMMARY
Intermittent enzalutamide in recurrent prostate cancer: testosterone kinetics and related toxicity.
Abstract summarizedQuality not appraised
- What was studied
- Whether testosterone changes tracked breast enlargement during intermittent enzalutamide treatment for recurrent prostate cancer.
- Who / model studied
- 38 patients with recurrent prostate cancer received intermittent 3-month enzalutamide courses without androgen-deprivation treatment. Testosterone and adverse events were monitored prospectively.
- Studied dose & schedule
- Dose and schedule were not reported in the source used for this summary.
- What the study found
- Median peak testosterone was 832.5 ng/dL. Breast-enlargement symptoms occurred in 42% of patients. Neither peak testosterone nor time with elevated testosterone correlated with these symptoms, and symptoms during one course did not reliably predict the next.
- Limitations & context
- This small prostate-cancer cohort does not establish what causes breast symptoms in other settings, such as testosterone therapy.
Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1111/bju.70443